173 related articles for article (PubMed ID: 20943770)
1. mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease.
Belibi F; Ravichandran K; Zafar I; He Z; Edelstein CL
Am J Physiol Renal Physiol; 2011 Jan; 300(1):F236-44. PubMed ID: 20943770
[TBL] [Abstract][Full Text] [Related]
2. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.
Ravichandran K; Zafar I; Ozkok A; Edelstein CL
Nephrol Dial Transplant; 2015 Jan; 30(1):45-53. PubMed ID: 25239638
[TBL] [Abstract][Full Text] [Related]
3. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic
Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL
Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.
Tao Y; Kim J; Schrier RW; Edelstein CL
J Am Soc Nephrol; 2005 Jan; 16(1):46-51. PubMed ID: 15563559
[TBL] [Abstract][Full Text] [Related]
6. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease.
Tao Y; Kim J; Faubel S; Wu JC; Falk SA; Schrier RW; Edelstein CL
Proc Natl Acad Sci U S A; 2005 May; 102(19):6954-9. PubMed ID: 15863619
[TBL] [Abstract][Full Text] [Related]
7. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD).
Zafar I; Belibi FA; He Z; Edelstein CL
Nephrol Dial Transplant; 2009 Aug; 24(8):2349-53. PubMed ID: 19321761
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL
Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448
[TBL] [Abstract][Full Text] [Related]
9. Concomitant use of rapamycin and rosiglitazone delays the progression of polycystic kidney disease in Han:SPRD rats: a study of the mechanism of action.
Liu C; Li H; Gao X; Yang M; Yuan L; Fu L; Wang X; Mei C
Am J Physiol Renal Physiol; 2018 May; 314(5):F844-F854. PubMed ID: 26911848
[TBL] [Abstract][Full Text] [Related]
10. Caspases, Bcl-2 proteins and apoptosis in autosomal-dominant polycystic kidney disease.
Ecder T; Melnikov VY; Stanley M; Korular D; Lucia MS; Schrier RW; Edelstein CL
Kidney Int; 2002 Apr; 61(4):1220-30. PubMed ID: 11918728
[TBL] [Abstract][Full Text] [Related]
11. [Effect of a modified low protein and low fat diet on histologic changes and metabolism in kidneys in an experimental model of polycystic kidney disease].
Banković-Calić N; Ogbori MR; Nicman E
Srp Arh Celok Lek; 2002; 130(7-8):251-7. PubMed ID: 12585002
[TBL] [Abstract][Full Text] [Related]
12. Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease.
Wahl PR; Le Hir M; Vogetseder A; Arcaro A; Starke A; Waeckerle-Men Y; Serra AL; Wuthrich RP
Nephrology (Carlton); 2007 Aug; 12(4):357-63. PubMed ID: 17635750
[TBL] [Abstract][Full Text] [Related]
13. Inflammation Is More Sensitive than Cell Proliferation in Response to Rapamycin Treatment in Polycystic Kidney Disease.
Yang M; Lv J; Gong C; Xue C; Fu L; Chen S; Mei C
Kidney Blood Press Res; 2024; 49(1):60-68. PubMed ID: 38167222
[TBL] [Abstract][Full Text] [Related]
14. Pivotal role of mTORC2 and involvement of ribosomal protein S6 in cardioprotective signaling.
Yano T; Ferlito M; Aponte A; Kuno A; Miura T; Murphy E; Steenbergen C
Circ Res; 2014 Apr; 114(8):1268-80. PubMed ID: 24557881
[TBL] [Abstract][Full Text] [Related]
15. Selective interference of mTORC1/RAPTOR protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism with Akt and autophagy induction.
Ito M; Yurube T; Kakutani K; Maeno K; Takada T; Terashima Y; Kakiuchi Y; Takeoka Y; Miyazaki S; Kuroda R; Nishida K
Osteoarthritis Cartilage; 2017 Dec; 25(12):2134-2146. PubMed ID: 28888905
[TBL] [Abstract][Full Text] [Related]
16. Altered ATP-sensitive P2 receptor subtype expression in the Han:SPRD cy/+ rat, a model of autosomal dominant polycystic kidney disease.
Turner CM; Ramesh B; Srai SK; Burnstock G; Unwin RJ
Cells Tissues Organs; 2004; 178(3):168-79. PubMed ID: 15655334
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil versus Rapamycin in Han: SPRD rats with Polycystic Kidney Disease.
Zhang T; Wang L; Xiong X; Mao Z; Wang L; Mei C
Biol Res; 2009; 42(4):437-44. PubMed ID: 20140299
[TBL] [Abstract][Full Text] [Related]
18. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin.
Toschi A; Lee E; Xu L; Garcia A; Gadir N; Foster DA
Mol Cell Biol; 2009 Mar; 29(6):1411-20. PubMed ID: 19114562
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin treatment augments both protein ubiquitination and Akt activation in pressure-overloaded rat myocardium.
Harston RK; McKillop JC; Moschella PC; Van Laer A; Quinones LS; Baicu CF; Balasubramanian S; Zile MR; Kuppuswamy D
Am J Physiol Heart Circ Physiol; 2011 May; 300(5):H1696-706. PubMed ID: 21357504
[TBL] [Abstract][Full Text] [Related]
20. A new in vitro bioassay for cyst formation by renal cells from an autosomal dominant rat model of polycystic kidney disease.
Pey R; Bach J; Schieren G; Gretz N; Hafner M
In Vitro Cell Dev Biol Anim; 1999; 35(10):571-9. PubMed ID: 10614866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
